Add to ORKGPhiladelphia chromosome-positive leukemias, including chronic myeloid leukemia and B-cell acute lymphoblastic leukemia (B-ALL), are driven by the oncogenic BCR-ABL fusion protein. Animal modeling experiments utilizing retroviral transduction and subsequen
grantor: University of TorontoThe activation of the T cell receptor (TCR) initiates an int...
The hallmark of Philadelphia chromosome positive (Ph+) leukemia is the BCR/ABL kinase, which is succ...
The hallmark of Philadelphia chromosome positive (Ph+) leukemia is the BCR/ABL kinase, which is succ...
Hematopoiesis describes the formation and development of blood cells. All blood cells originate fro...
Tyrosine kinase inhibitors (TKIs) directed against BCR-ABL1, the product of the Philadelphia (Ph) ch...
The BCR/ABL oncogene causes chronic myelogenous leukemia (CML) in humans and a CML-like disease, as ...
AbstractThe BCR/ABL oncogene causes chronic myelogenous leukemia (CML) in humans and a CML-like dise...
The BCR/ABL oncogene results from a balanced translocation between chromosomes 9 and 22 and is found...
BCR-ABL1 is a gene product of the t(9, 22) chromosomal translocation. It encodes a fusion protein wi...
BCR-ABL1-targeting tyrosine kinase inhibitors (TKIs) have revolutionized treatment of Philadelphia c...
A direct binding site for the Grb2 adapter protein is required for the induction of fatal chronic my...
Hematopoietic stem cells (HSCs) are the source of all blood lineages, and HSCs must balance quiescen...
AbstractBiological function of the BCR-ABL oncogene is dependent on its activated tyrosine kinase. M...
The effect of mutations in the Src homology 2 (SH2) domain of the BCR/ABL oncogene on leukemogenesis...
The successful targeting of BCR/ABL by selective ABL-kinase inhibitors (AKI) such as Imatinib, Nilot...
grantor: University of TorontoThe activation of the T cell receptor (TCR) initiates an int...
The hallmark of Philadelphia chromosome positive (Ph+) leukemia is the BCR/ABL kinase, which is succ...
The hallmark of Philadelphia chromosome positive (Ph+) leukemia is the BCR/ABL kinase, which is succ...
Hematopoiesis describes the formation and development of blood cells. All blood cells originate fro...
Tyrosine kinase inhibitors (TKIs) directed against BCR-ABL1, the product of the Philadelphia (Ph) ch...
The BCR/ABL oncogene causes chronic myelogenous leukemia (CML) in humans and a CML-like disease, as ...
AbstractThe BCR/ABL oncogene causes chronic myelogenous leukemia (CML) in humans and a CML-like dise...
The BCR/ABL oncogene results from a balanced translocation between chromosomes 9 and 22 and is found...
BCR-ABL1 is a gene product of the t(9, 22) chromosomal translocation. It encodes a fusion protein wi...
BCR-ABL1-targeting tyrosine kinase inhibitors (TKIs) have revolutionized treatment of Philadelphia c...
A direct binding site for the Grb2 adapter protein is required for the induction of fatal chronic my...
Hematopoietic stem cells (HSCs) are the source of all blood lineages, and HSCs must balance quiescen...
AbstractBiological function of the BCR-ABL oncogene is dependent on its activated tyrosine kinase. M...
The effect of mutations in the Src homology 2 (SH2) domain of the BCR/ABL oncogene on leukemogenesis...
The successful targeting of BCR/ABL by selective ABL-kinase inhibitors (AKI) such as Imatinib, Nilot...
grantor: University of TorontoThe activation of the T cell receptor (TCR) initiates an int...
The hallmark of Philadelphia chromosome positive (Ph+) leukemia is the BCR/ABL kinase, which is succ...
The hallmark of Philadelphia chromosome positive (Ph+) leukemia is the BCR/ABL kinase, which is succ...